The Summary
This retrospective cohort study compared 10,339 tirzepatide patients with 10,339 propensity-matched semaglutide patients using electronic health records over two years. Researchers analyzed weight-loss trajectories, demographic differences, and side effects using AI-enabled clinical note curation. Tirzepatide-treated patients achieved significantly greater average weight loss (14.7% versus 10.8%) and faster monthly weight-loss velocity. Furthermore, tirzepatide-treated patients were twice as likely to achieve high-response rates (losing 15% or more in year one) and reported lower rates of gastrointestinal and systemic side effects compared to those on semaglutide.
Why this is interesting
While clinical trials show both drugs work, this large-scale, real-world comparison confirms tirzepatide is more effective and better tolerated than semaglutide. Surprisingly, the study also revealed demographic differences: women and White patients were more likely to be high responders, while Black and Hispanic patients were overrepresented among minimal responders. For patients, this means tirzepatide may offer superior results with fewer side effects, but it also highlights a critical need for researchers to understand how genetics, lifestyle, and healthcare access influence how different populations respond to these blockbuster therapies.